MICHIGAN PHARMACISTS ASSOCIATION AND CLASS ACTION CAPITAL PARTNERSHIP PORTAL
Many healthcare companies do not have the time, resources, or relevant data available to file a settlement claim and Class Action Capital will work with you in order to submit a fully comprehensive claim recovery while minimizing your time, internal resources, and the risk of error if you were to take on this process on your own.
Generic Pharmaceutical Pricing Antitrust Litigation
The lawsuit claims that generic drug manufacturers violated antitrust laws, harming competition and causing settlement class members to overpay for over 150 Named Generic Drugs between May 1, 2009 through December 31, 2019.
The defendant list includes 58 of the country’s major generic drug manufacturers; the settling defendants deny liability as alleged in the lawsuit and the court has not decided who is right or wrong.
Currently, Sun Pharmaceutical Industries and Taro Pharmaceuticals USA have settled for a combined total of $85 million but it is Class Action Capital’s opinion that this could be among the largest settlements in US history.
There are three potential classes your organization may qualify for depending on how your organization purchases these products and for what purpose: Direct, Indirect, and End Payor.
SureScripts Antitrust Litigation
The case involves the market that digitally transmits prescriptions from the prescribing physician to the pharmacy. The market involves (1) routing prescriptions to pharmacies, and (2) the eligibility market that allows providers to check a patient’s insurance eligibility.
The prescribing physicians contract with electronic health records (EHR) vendors to convey prescription information to pharmacies’ computer databases across an e-prescribing network. In a separate but related transaction, the patient’s formulary and pharmaceutical benefit information goes from the patient’s healthcare plan (usually the patient’s health insurer or pharmacy benefit manager) to the prescriber physician’s EHR system.
SureScripts is the go-between for pharmacies and the providers who send them prescriptions, and it also serves as the go-between providers and pharmacy benefit managers who check the patient’s eligibility.
Payment Card Antitrust Litigation
This settlement resolves allegations that VISA, MasterCard and their issuing banks violated the law by charging excessive interchange fees to merchants. The settlement received final approval on December 13, 2019 and the settlement fund is approximately $5.54 billion. Your organization is likely eligible for a refund if you accepted VISA or MasterCard branded credit or debit cards as a form of payment between January 1, 2004 – January 25, 2019.
While claim forms are not yet available and potential claimants do not need to sign up with a third-party service in order to participate in any monetary relief, the difficulty may be understanding what information will be provided by the defendants, how that applies to your organization, as well as what additional information can be provided to the court administrator to ensure a complete claim.
No-cost assistance will be available from the court administrator and class counsel during the claim filing period. If the Court grants the settlement final approval and any appeals are resolved, the Court will approve a claim process and establish a claim deadline. Updates about the settlement can be found on the official court authorized settlement website at: https://www.paymentcardsettlement.com